Search | Clinical Trials Finder

Conditions: Colitis, Ulcerative
Interventions: Vedolizumab, Adalimumab placebo, Adalimumab, Vedolizumab placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 771 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 77
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo matched to atacicept, Atacicept: with loading dose, Atacicept, Adalimumab; Drug · Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab, Adalimumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 11
States / cities: Los Angeles, California • Coral Gables, Florida • Orange, Florida + 8 more

Conditions: Uveitis, JIA
Interventions: Adalimumab, Placebo; Biological · Other
Lead sponsor: Nisha Acharya; Other
Eligibility: 2 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Ankylosing Spondylitis
Interventions: Placebo, GP2017 (adalimumab biosimilar), AIN457 150 mg; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 19
States / cities: Mesa, Arizona • Escondido, California • La Mesa, California + 16 more

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 48
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Ulcerative Colitis
Interventions: adalimumab, placebo; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 36
States / cities: Anaheim, California • Wheat Ridge, Colorado • Hamden, Connecticut + 29 more

Conditions: REM Sleep Behavior Disorder
Interventions: Adalimumab, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Los Angeles, California • Aurora, Colorado • North Haven, Connecticut + 14 more

Conditions: Rheumatoid Arthritis
Interventions: GDC-0853, Adalimumab, Folic Acid, MTX, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more

Conditions: Psoriatic Arthritis
Interventions: Filgotinib, Adalimumab, Placebo to match filgotinib, Placebo to match adalimumab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 24
States / cities: Covina, California • Brandon, Florida • DeBary, Florida + 20 more

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Placebo; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Orlando, Florida + 11 more

Conditions: Ulcerative Colitis
Interventions: adalimumab, placebo; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 29
States / cities: Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 25 more

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 9
States / cities: Lakewood, Colorado • Maitland, Florida • Naples, Florida + 6 more

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 4
States / cities: Orlando, Florida • Topeka, Kansas • Mentor, Ohio

Conditions: Rheumatoid Arthritis
Interventions: Lutikizumab, Placebo, Ravagalimab, ABBV-8736, ABBV-701, ABBV-848, Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 49
States / cities: Peoria, Arizona • Jonesboro, Arkansas • Beverly Hills, California + 42 more

Conditions: Rheumatoid Arthritis
Interventions: Etanercept, Infliximab, Adalimumab, Placebo; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI
Interventions: Adalimumab, Placebo; Drug · Other
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 5 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Torrance, California

Conditions: Rheumatoid Arthritis
Interventions: Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 85
States / cities: Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more

Conditions: Hidradenitis Suppurativa
Interventions: PTM-001, Placebo; Drug
Lead sponsor: Phoenicis Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Redwood City, California • Worcester, Massachusetts • Cincinnati, Ohio

Conditions: Crohn Disease
Interventions: JNJ-64304500, Placebo, Adalimumab, Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Crohn's Disease
Interventions: Adalimumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more

Conditions: Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
Interventions: Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX), Placebo SC, Placebo IV; Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 89
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more

Conditions: Psoriatic Arthritis
Interventions: Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1,705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 114
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more

Conditions: Hidradenitis Suppurativa
Interventions: adalimumab, Placebo; Biological · Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Birmingham, Alabama • Bakerfield, California • Los Angeles, California + 15 more

Search by objective public record fields.

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Adalimumab in JIA-associated Uveitis Stopping Trial

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa

A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa